Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers

Recent clinical trials with selective inhibitors of the BRAF and MEK kinases have shown promising results in patients with tumors harboring BRAF V600 mutations. However, as has been observed previously with similarly successful targeted therapies, acquired resistance to these agents is an emerging p...

Descripción completa

Detalles Bibliográficos
Autores principales: Corcoran, Ryan B., Settleman, Jeffrey, Engelman, Jeffrey A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2011
Materias:
Research Perspectives
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3248170/
https://www.ncbi.nlm.nih.gov/pubmed/21505228

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3248170/
https://www.ncbi.nlm.nih.gov/pubmed/21505228

Ejemplares similares